{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:38:48Z","timestamp":1793252328464,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.anai.2019.08.014","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T06:05:54Z","timestamp":1566540354000},"page":"2-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["New treatments for chronic urticaria"],"prefix":"10.1016","volume":"124","author":[{"given":"Pavel","family":"Kolkhir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hawro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.08.014_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria: a GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.iac.2013.09.011","article-title":"Urticaria: impact on quality of life and economic cost","volume":"34","author":"O'Donnell","year":"2014","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.anai.2019.08.014_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/all.12068","article-title":"Psychosocial factors and chronic spontaneous urticaria: a systematic review","volume":"68","author":"Ben-Shoshan","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4168\/aair.2019.11.1.29","article-title":"Causal relationship between anti-TPO IgE and chronic urticaria by in\u00a0vitro and in\u00a0vivo tests","volume":"11","author":"S\u00e1nchez","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.anai.2019.08.014_bib7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/all.13587","article-title":"Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria","volume":"73","author":"Cugno","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2019.08.014_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.alit.2019.01.003","article-title":"Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce Fc\u03b5RI crosslinking, as compared to anti-Fc\u03b5RI\u03b1 AAbs","volume":"68","author":"Izaki","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.anai.2019.08.014_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of 'real-world' evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.anai.2019.08.014_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.13845","article-title":"Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment","volume":"173","author":"Urgert","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib12","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.anai.2018.06.014","article-title":"Omalizumab chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response","volume":"121","author":"Nettis","year":"2018","journal-title":"Annals Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib17","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil FceRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derml Venereol"},{"key":"10.1016\/j.anai.2019.08.014_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000491530","article-title":"Omalizumab updosing for better disease control in chronic spontaneous urticaria patients","volume":"177","author":"Kocat\u00fcrk","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.08.014_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.anai.2019.05.003","article-title":"Omalizumab for chronic urticaria in children younger than 12 years of age","volume":"123","author":"Al-Shaikhly","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.13621","article-title":"Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u2018idiopathic\u2019) urticaria","volume":"172","author":"Kay","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1590\/abd1806-4841.20165066","article-title":"Correlation between the histopathology of chronic urticaria and its clinical picture","volume":"91","author":"Marques","year":"2016","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ddg.13481","article-title":"Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria","volume":"16","author":"Magerl","year":"2018","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.anai.2019.08.014_bib26","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/jdv.14594","article-title":"Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria","volume":"32","author":"Maurer","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2019.08.014_bib27","author":"Bergmann"},{"key":"10.1016\/j.anai.2019.08.014_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2019.08.014_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2004.07.006","article-title":"Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria","volume":"36","author":"Caproni","year":"2004","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.anai.2019.08.014_bib30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib31","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2019.08.014_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/all.12389","article-title":"Chronic urticaria and coagulation: pathophysiological and clinical aspects","volume":"69","author":"Tedeschi","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000292947","article-title":"Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study","volume":"152","author":"Asero","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/09546634.2017.1329505","article-title":"Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence","volume":"29","author":"Holm","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.anai.2019.08.014_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2340\/0001555557369370","article-title":"Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study","volume":"57","author":"Laurberg","year":"1977","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.anai.2019.08.014_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000058004","article-title":"Immune profiles of patients with chronic idiopathic urticaria","volume":"128","author":"Piconi","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0091-6749(99)70506-3","article-title":"Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria","volume":"103","author":"Hermes","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.anai.2019.08.014_bib39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jaad.2009.10.043","article-title":"Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors","volume":"64","author":"Wilson","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000487402","article-title":"Rituximab in refractory chronic spontaneous urticaria: an encouraging therapeutic approach","volume":"31","author":"Combalia","year":"2018","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.anai.2019.08.014_bib41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study","volume":"132","author":"Krause","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-157-8-201210160-00023","article-title":"Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria","volume":"157","author":"Lenormand","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2019.08.014_bib43","first-page":"302","article-title":"Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra)","volume":"67","author":"Bodar","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.anai.2019.08.014_bib44","unstructured":"Bingham III C, Towns M, Bartlett S. Pilot study of abatacept in patients with refractory autoimmune chronic urticaria. Paper presented at: ACR\/ARHP Annual Meeting; October 25, 2013; San Diego, California. Abstract\u00a02040."},{"key":"10.1016\/j.anai.2019.08.014_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.anai.2009.12.007","article-title":"Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria","volume":"104","author":"Mitzel-Kaoukhov","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s13223-017-0197-6","article-title":"The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria","volume":"13","author":"Grzanka","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib47","doi-asserted-by":"crossref","first-page":"17797","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.anai.2019.08.014_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.08.014_bib50","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaci.2015.06.004","article-title":"Altered expression of chemoattractant receptor\u2013homologous molecule expressed on TH2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria","volume":"137","author":"Oliver","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib51","doi-asserted-by":"crossref","first-page":"AB401","DOI":"10.1016\/j.jaci.2015.12.1242","article-title":"A\u00a0trial of an oral CRTH2 antagonist in antihistamine-refractory chronic spontaneous urticaria","volume":"137","author":"Oliver","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib53","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.anai.2019.08.014_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12016-012-8326-y","article-title":"Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema","volume":"45","author":"Altman","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.anai.2019.08.014_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clim.2009.05.003","article-title":"Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2","volume":"132","author":"Saini","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib57","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bph.14610","article-title":"GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex\u00a0vivo human skin","volume":"176","author":"Ramirez Molina","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.anai.2019.08.014_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s12948-018-0101-z","article-title":"Focus on the role of substance P in chronic urticaria","volume":"16","author":"Vena","year":"2018","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.anai.2019.08.014_bib59","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/jid.2014.226","article-title":"Substance P is upregulated in the serum of patients with chronic spontaneous urticaria","volume":"134","author":"Metz","year":"2014","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00065","article-title":"The histamine H4 receptor: from orphan to the clinic","volume":"6","author":"Thurmond","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.anai.2019.08.014_bib61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.114.215749","article-title":"The histamine H4 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects","volume":"350","author":"Kollmeier","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2019.08.014_bib62","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0091-6749(99)70129-6","article-title":"Complement dependence of histamine release in chronic urticaria","volume":"104","author":"Ferrer","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/mai.2002.120954","article-title":"A\u00a0role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria","volume":"109","author":"Kikuchi","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib65","series-title":"Mast Cell Biology: Contemporary and Emerging Topics","first-page":"143","article-title":"Down-regulation of mast cell responses through ITIM containing inhibitory receptors","author":"Karra","year":"2011"},{"key":"10.1016\/j.anai.2019.08.014_bib66","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaci.2006.04.031","article-title":"Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a","volume":"117","author":"Bachelet","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00175","article-title":"Current strategies to inhibit high affinity Fc\u03b5RI-mediated signaling for the treatment of allergic disease","volume":"10","author":"Gomez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2019.08.014_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/IR:34:2:97","article-title":"Development, migration, and survival of mast cells","volume":"34","author":"Okayama","year":"2006","journal-title":"Immunol Res"},{"key":"10.1016\/j.anai.2019.08.014_bib69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ced.13254","article-title":"In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are\u00a0linked to recurrent angio-oedema","volume":"43","author":"Terhorst","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.anai.2019.08.014_bib70","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0091-6749(96)70128-8","article-title":"Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1 alpha, stem cell factor, anti-IgE, and codeine as determined by an ex\u00a0vivo skin microdialysis technique","volume":"98","author":"Petersen","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.1016\/j.anai.2021.11.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000}}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619306039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619306039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:09:58Z","timestamp":1695121798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619306039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1081120619306039"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.08.014","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.anai.2021.11.016","asserted-by":"object"}]},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments for chronic urticaria","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}